Recent insights on the pro-apoptotic phenotype elicited by presenilin 2 and its caspase and presenilinase-derived fragments

Current Alzheimer Research

Volumn 2, Issue 5, 2005, Pages 507-514

  Alves Da Costa, Cristine ^a  

^a CNRS   (France)

Author keywords

Alzheimer's disease; Apoptosis; Caspases; Pesenilinase; Presenilins

Indexed keywords

CASPASE; ISOENZYME; PRESENILIN 1; PRESENILIN 2; PRESENILINASE; PROTEIN; PROTEIN BAX; PROTEIN P53; UBIQUITIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 1; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; HUMAN; NEUROPATHOLOGY; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SEQUENCE HOMOLOGY;

EID: 28244432573     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720505774932278     Document Type: Review

References (108)

1. Selkoe DJ. Alzheimer's disease: Genotypes phenotypes and treatments. Science 275: 630-631 (1997).
2. Hardy J. and Duff K. Heterogeneity in Alzheimer's disease. Ann Med 25: 437-440 (1993).
3. Tanzi RE. and Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 32: 181-184 (2001).
4. Hardy J. Amyloid the presenilins and Alzheimer's disease. TINS 20: 154-159 (1997).
5. Van Broeckhoven C. Presenilins and Alzheimer disease. Nature Genetics 11: 230-232 (1995).
6. Sun Y.-H. and Checler F. Amyloid precursor protein presenilins and α-synuclein: Molecular pathogenesis and pharmacological applications in Alzheimers' disease. Pharmacol Rev 54: 469-525 (2002).
7. Hardy J. and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends in Pharmacol Sci 12: 383-388 (1991).
8. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 6: 487-498 (1991).
9. Hardy JA. and Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185 (1992).
10. Checler F. Presenilins: multifunctional proteins involved in Alzheimer's disease pathology. Iubmb LIFE 48: 33-39 (1999).
11. Sisodia SS. and St.George-Hyslop P. γ-secretase notch Aβ and Alzheimer's disease: where do the presenilins fit in?. Nat Rev Neurosci 3: 281-290 (2002).
12. Octave JN. The amyloid peptide and its precursor in Alzheimer's disease. Rev in Neurosci 6: 287-316 (1995).
13. Cotman CW. Apoptosis decision cascades and neuronal degeneration in Alzheimer's disease. Neurobiol of Aging 19: S29-S32 (1998).
14. Cotman CW. and Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Molecular Neurobiology 10: 19-45 (1995).
15. Smale G, Nichols NRD, Brady R. and Finch CE. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 133: 225-230 (1995).
16. Su JH, Anderson AJB, Cummings J. and Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport 5: 2529-2533 (1994).
17. Salvesen GS. and Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 91: 443-446 (1997).
18. Zhivotovski B, Samali A, Gahm A. and Orrenius S. Caspases: their intracellular localization and translocation during apoptosis. Cell death & diff 6: 644-651 (1999).
19. Kumar S. Mechanisms mediating caspase activation in cell death. Cell death & diff 6: 1060-1066 (1999).
20. Rohn TT, Head E, Nesse WH.C, Cotman W. and Cribbs DH. Activation of caspase 8 in the Alzheimer's disease brain. Neurobiol. of Dis 8: 1006-1016 (2001).
21. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW. and Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol of Dis 11: 341-354 (2002).
22. Stadelmann C, Deckwerth T, Srinivasan A, Bancher CW, Jellinger BK. and Lassmann H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Am J Pathol 155: 1459-1466 (1999).
23. Su J.H, Kesslak JP. and Head E. Caspase-cleaved amyloid precursor protein and activated caspase-3 are co-localized in the granules of granulovacuolar degeneration in Alzheimer's disease and down's syndrome brain. Acta Neuropathol 104: 1-6 (2002).
24. Zhao M, Su JH, Head E. and Cotman CW. Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol of Dis 14: 391-403 (2003).
25. Kitamura Y, Shimohama S, Kamoshima WT, Ota Y, Matsuoka Y, Nomura MA, Smith G, Perry PJ. and Taniguchi T. Alteration of proteins regulating apoptosis. Bcl-2 Bcl-X bax Bak Bad ICH-1 and CPP32 in Alzheimer's disease. Brain Res 780: 260-269 (1998).
26. Weidemann A, Paliga K, Dürrwang U, Reinhard FBM, Schuckert O, Evin G. and Masters CL. Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. J Biol Chem 274: 5823-5829 (1999).
27. Gervais FGD, Xu GS, Robertson JP, Vaillancourt Y, Zhu J, Huang A, LeBlanc D, Smith M, Rigby MS, Shearman EE, Clarke H, Zheng LHT, Van Der Ploeg SC, Ruffolo NA, Thornberry S, Xanthoudakis RJ, Zamboni S. and Nicholson DW. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid β precursor protein and amyloidogenic Aβ peptide formation. Cell 97: 395-406 (1999).
28. Pellegrini L. Passer BJ, Tabaton M, Ganjei JK. and D'Adamio L. Alternative non-secretase processing of Alzheimer's b-amyloid precursor protein during apoptosis by caspase-6 and -8. J Biol Chem 274: 21011-21016 (1999).
29. Tanzi RE. Caspases land on APP: one small step for apoptosis one giant leap for amyloidosis. Nature Neuroscience 2: 585-586 (1999).
30. Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LMX, Ye GS, Salvesen E, Koo H. and Bredesen DE. A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor. Nat Medicine 6: 397-404 (2000).
31. Kim H-S, Kim E-M, Lee J-P, Park C-H, Kim SJ, Seo J-H, Chang K-A, Yu E, Jeong S-J, Chong YH. and Suh Y-H. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3β expression. FASEB J 17: 1951-1953 (2003).
32. C. Dumanchin-Njock C. Alves da Costa L. Mercken L. Pradier and F. Checler The caspase-derived C-terminal fragment of βAPP induces caspase- independent toxicity and triggers selective increase of Aβ42 in mammalian cells. J Neurochem 78: 1153-1161 (2001).
33. Xu X, Yang D, Wyss-Coray T, Yan J, Gan L. and Mucke L. Wild-type but not alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc Natl Acad Sci USA 22: 7547-7552 (1999).
34. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ. and Cotman CW. Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 90: 7951-7955 (1993).
35. Watt JA, Pike CJ, Walencewicz-Wasserman AJ. and Cotman CW. Ultrastructural analysis of beta-amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res. 661: 147-156 (1994).
36. Zou K, Kim D, Kakio A, Byun K, Gong J-S, Kim J, Kim M, Sawamura Nishimoto S-iN, Matsuzaki K, Lee B, Yanagisawa K. and Michikawa M. Amyloid β-protein (Aβ)1-40 protects neurons from damage induced by Aβ1-42 in culture and in rat brain. J Neurochem 87: 609-619 (2003).
37. Plant LD, Boyle JP, Smith IF, Peers C. and Pearson HA. The production of amyloid β peptide is a critical requirement for the viability of central neurons J Neurosci 23: 5531-5535 (2003).
38. Saura CA, Choi S-Y, Beglopoulos V, Malkani S, Zhang D, Rao BSS, Chattarji S, Kelleher III RJ, Kandel ER, Duff K, Kirkwood A. and Shen J. Loss of presenilin function causes impairements of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42: 23-36 (2004).
39. Beglopoulos V, Sun X, Saura CA, Lemere CA, Kim RD. and Shen J. Reduced β-amyloid production and increased inflammatory response in presenilin conditional knockout mice. J Biol Chem 279: 46566-46572 (2004).
40. Levy-Lahad E, Poorkaj P, Wang K, Fu YH, Oshima J, Mulligan J. and Schellenberg GD. Genomic structure and expression of STM2 the chromosome 1 familial Alzheimer disease gene. Genomics 34: 198-204 (1996).
41. Prihar G, Fuldner RA, Perez-Tur J, Lincoln S, Duff K, Crook R, Hardy J, Philips CA, Venter C, Talbot C, Clark RF, Goate A, Li J, Potter H, Karran E, Roberts GW, Hutton M. and Adams MD. Structure and alternative splicing of the presenilin-2 gene. NeuroReport 7: 1680-1684 (1996).
42. Doan A, Thinakaran G, Borchelt D.R, Slunt HH, Ratovitsky T, Podlisny M, Selkoe D.J, Seeger M, Gandy SE, Price DL. and Sisodia SS. Protein topology of presenilin 1. Neuron 17: 1023-1030 (1996).
43. Lehmann S, Chiesa R. and Harris DA. Evidence for a six-transmembrane domain structure of presenilin 1. J Biol Chem 272: 12047-12051 (1997).
44. Li X. and Greenwald I. Membrane topology of the C-elegans SEL-12 Presenilin J Biol Chem 17: 1015-1021 (1996).
45. Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki KT, S, Capell A, Walter J, Grünberg J, Haass C, Iwatsubo T. and Obata K. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 94: 2025-2030 (1997).
46. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacana E, Sunderland T, Zhao B, Kusiak JW, Wasco W. and D'Adamio L. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 274: 1710-1713 (1996).
47. Benkovic SA, McGowan E, Rothwell N, Hutton M, Morgan DG. and Gordon MN. Regional and cellular localization of presenilin-2 RNA in rat and human brain. Exp Neurol 145: 555-564 (1997).
48. De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, Cordell B, Moechars D, Bollen M, Fraser P, St. George-Hyslop P. and Van Leuven F. Phosphorylation subcellular localization and membrane orientation of the Alzheimer's disease-associated presenilins. J Biol Chem 272: 3590-3598 (1997).
49. Kovacs DM, Fausett HJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, Hyman BT, Tanzi RE. and Wasco W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nature Medicine 2: 224-229 (1996).
50. Walter J, Capell A, Grünberg J, Pesold B, Schindzielorz A, Prior R, Podlisny MB, Fraser P, St. George Hyslop P, Selkoe DJ. and Haass C. The Alzheimer's disease-associated presenilins are differentially phosphorylated proteins located predominantly within the endoplasmic reticulum. Mol. Medecine 2: 673-691 (1996).
51. Dewji NN. and Singer SJ. Cell surface expression of the Alzheimer disease-related presenilin proteins. Proc Natl Acad Sci USA 94: 9926-9931 (1997).
52. Takashima A, Sato M, Mercken M, Tanaka S, Honda T, Sato K, Murayama M, Noguchi K, Nakazato Y. and Takahashi H. Localization of Alzheimer-associated presenilin1 in transfected COS-7 cells. Biochem Biophys Res Commun 227: 423-426 (1996).
53. Li J, Xu M, Zhou H, Ma J. and Potter H. Alzheimer presenilins in the nuclear membrane interphase kinetochores and centrosomes suggest a role in chromosome seggregation. Cell 90: 917-927 (1997).
54. Checler F. Presenilins: Structural aspects and post-translational events Mol Neurobiol 19: 255-265 (1999).
55. Marambaud P, Ancolio K, Lopez-Perez E. and Checler F. Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and trigger increased Aβ42 secretion by human cells. Mol Medicine 4: 147-157 (1998).
56. Kim TW, Pettingell WH, Hallmark OG, Moir RD, Wasco W. and Tanzi R. E. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J Biol Chem 272: 11006-11010 (1997).
57. Janicki S. and Monteiro M. J. Increased apoptosis arising from increased expression of the Alzheimer's disease associated presenilin-2 mutation (N141I). J Cell Biol 139: 485-495 (1997).
58. Deng G, Pike CJ. and Cotman CW. Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells. FEBS Lett 397: 50-54 (1996).
59. Alves da Costa C, Paitel E, Mattson MP, Amson R, Telerman A, Ancolio K. and Checler F. Wild-type and mutated presenilin-2 trigger p53-dependent apoptosis and down-regulate presenilin-1 expression in HEK293 human cells and in murine neurons. Proc Natl Acad Sci USA 99: 4043-4048 (2002).
60. WAF-1 and results in apoptosis and tumor suppression. Nature Medicine 4: 835-838 (1998).
61. Amson R, Lassalle J-M, Halley H, Prieur S, Lethrosne F, Roperch J-P, Isreali D, Gendron M-C, Duyckaerts C, Checler F, Dausset J, Cohen D, Oren M. and Telerman A. Behavioral alterations associated with apoptosis and down-regulation of presenilin 1 in the brains of p53-deficient mice. Proc Natl Acad Sci USA 97: 5346-5350 (2000).
62. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV. and Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effect of cancer therapy. Science 285: 1733-1737 (1999).
63. Sun J, Li M, Han J. and Gu J. Sensitization of differentiated PC12 cells to apoptosis by presenilin-2 is mediated by p38. Biochem Biophys Res Commun 287: 536-541 (2001).
64. Zhu Y, Mao XO, Sun Y, Xia Z. and Greenberg DA. p38 mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons. J Biol Chem 277: 22909-22914 (2002).
65. KB-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem 277: 33501-33508 (2002).
66. Miyashita T. and Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299 (1995).
67. Xiang H, Kinoshita Y, Knudson CM, Korsmeyer SJ, Schwartzkroin PA. and Morrison RS. Bax involvement in p53-mediated neuronal cell death. J Neurosci 18: 1363-1373 (1998).
68. Passer BJ, Pellegrini L, Vito P, Ganjei JK. and D'Adamio L. Interaction of Alzheimer's presenilin-1 and presenilin-2 with bcl-XL: A potential role in modulating the threshold of cell death. J Biol Chem 274: 24007-24013 (1999).
69. Mori M, Nakagami H, Morishita R, Mitsuda N, Yamamoto K, Yoshimura S.-i, Ohkubo N, Sato N, Ogihara T. and Kaneda Y. N141I mutant presenilin-2 gene enhances neuronal cell death and decreases bcl-2 expression. Life Sci 70: 2567-2580 (2002).
70. Bence NF, Sampat RM. and Kopito RR. Impairement of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555 (2001).
71. Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 101: 451-454 (2000).
72. Zhang K. and Kaufman RJ. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 279: 25935-25938 (2004).
73. Zong WX, Li C, Hatzivassiliou G, Lindsten T, Yu QC, Yuan J. and Thompson C. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol 162: 59-69 (2003).
74. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA. and Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 403: 98-103 (2000).
75. Leissring MA, Paul BA, Parker I, Cotman CW. and LaFerla FM. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphophate-mediated calcium signaling in Xenopus oocytes. J Neurochem 72: 1061-1068 (1999).
76. Yoo AS, Cheng I, Chung ST, Grenfell Z, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, Saunders AJ, Ding K, Frosch MP, Tanzi RE. and Kim TW. Presenilin-mediated modulation of capacitative calcium entry. Neuron 27: 561-572 (2000).
77. Buxbaum JD, Choi E-K, Luo Y, Lilliehook C, Crowley ACD, Merriam E. and Wasco W. Calsenilin: A calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nature Medicine 4: 1177-1181 (1998).
78. Pack-Chung E, Meyers MB, Pettingell WP, Moir RD, Brownawell AM, Cheng I, Tanzi RE. and Kim T-W. Presenilin 2 interacts with sorcin a modulator of the ryanodine receptor. J Biol Chem 275: 14440-14445 (2000).
79. Stabler SM, Ostrowski LL, Janicki SM. and Monteiro MJ. A myristoylated calcium-binding protein that preferentially interacts with the Alzheimer's disease presenilin 2 protein. J Cell Biol 145: 1277-1292 (1999).
80. Maruyama K, Usami M, Kametani F, Tomita T, Iwatsubo T, Saido TC, Mori H. and Ishiura S. Molecular interaction between presenilin and calpain: inhibition of m-calpain protease activity by presenilin-1,2 and cleavage of presenilin-1 by μ- mu-calpain. Int J Mol Med 5: 269-273 (2000)
81. Katayama T, Imaizumi K, Sato N, Miyoshi Kudo KT, Hitomi J, Morihara T, Yoneda T, Gomi F, Mori Y, Nakano Y, Takeda J, Tsuda T, Itotama Y, Murayama O, Takashima A, St. George-Hyslop P, Takeda M. and Tohyama M. Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nature Cell Biol 1: 479-485 (1999).
82. Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, Takeda M, Mori K, Rozmahel R, Fraser P, St. George-Hyslop P. and Tohyama M. Disturbed activation of endoplasmic stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. J Biol Chem 276: 43446-43454 (2001).
83. Niwa M, Sidrauski C, Kaufman RJ. and Walter P. A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response. Cell 99: 691-702 (1999).
84. Sato N, Urano F, Leem JY, Kirn S-H, Li M, Donoviel DB, Bernstein B, Lee AS, Ron D, Veselits ML, Sisodia SS. and Thinakaran G. Upregulation of BiP and CHOP by the unfolded-protein response is independent of presenilin expression. Nat Cell Biol 2: 863-870 (2000).
85. Steiner H, Winkler E, Shearman MS, Prywes R. and Haass C. Endoproteolysis of the ER stress transducer ATF6 in the presence of functionally inactive presenilins. Neurobiol of Dis 8: 717-722 (2001).
86. Imaizumi K, Miyoshi K, Katayama T, Yoneda T, Taniguchi M, Kudo T. and Tohyama M. The unfolded protein response and Alzheimer's disease. Biochim Biophys Acta 1536: 85-96 (2001).
87. Sato N, Hori O, Yamaguchi A, Lambert J-C, Chartier-Harlin M-C, Robinson PA, Delacourte A, Schmidt A, Furuyama T, Imaizumi K, Tohyama M. and Takagi A novel Presenilin-2 splice variant in human Alzheimer's disease brain tissue. J Neurochem 72: 2498-2505 (1999).
88. Sato N, Imaizumi K, Manabe T, Taniguchi M, Hitomi J, Katayama T, Yoneda T, Morihara T, Yasuda Y, Takagi T, Kudo T, Tsuda T, Itoyama Y, Makifichi T, Fraser PE, St George-Hyslop P. and Tohyama M. Increased production of β-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. J Biol Chem 276: 2108-2114 (2001).
89. Matsuzaki S, Manabe T, Katayama T, Nishikawa A, Yanagita T, Okuda H, Yasuda Y, Miyata S, Meshitsuka S. and Tohyama M. Metal accelerate production of the aberrant splicing isoform of the presenilin-2. J. Neurochem 88: 1345-1351 (2004).
90. Shirotani K, Takahashi K, Araki W, Maruyama K. and Tabira T. Mutational analysis of intrinsic regions of presenilin 2 that determine its endoproteolytic cleavage and pathological function. J Biol Chem 275: 3681-3686 (2000).
91. Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL. and Sisodia SS. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nature Medicine 3: 756-760 (1997).
92. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL. and Sisodia S. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17: 181-190 (1996).
93. Capell A, Grünberg J, Pesold B, Diehlmann A, Citron M, Nixon R, Beyreuther K, Selkoe DJ. and Haass C. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass. J Biol Chem 273: 3205-3211 (1998).
94. Thinakaran G, Regard JB, Bouton CML, Harris CL, Price DL, Borchelt DR. and Sisodia SS. Stable association of presenilin derivatives and absence of presenilin interactions with APP. Neurobiol Dis 4: 438-453 (1998).
95. Kim T-W, Pettingell WH, Jung Y-K, Kovacs DM. and Tanzi RE. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 277: 373-376 (1997).
96. van de Craen M, de Jonghe C, van den Brande I, Declercq W, van Gassen G, van Criekinge W, Vanderhoeven I, Fiers W, van Broeckhoven C, Hendricks L. and Vandenabeele P. Identification of caspases that cleave presenilin-1 and presenilin-2. Five presenilin-1 (PS1) mutations do not alter the sensitivity of PS1 to caspases. Neurosci lett 260: 149-154 (1999).
97. Vito P, Ghayur T. and D'Adamio L. Generation of anti-apoptotic presenilin-2 polypeptides by alternative transcription proteolysis and caspase-3 cleavage. J Biol Chem 272: 28315-28320 (1997).
98. Walter J, Schindzielorz A, Grünberg J. and Haass C. Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis. Proc Natl Acad Sci USA 96: 1391-1396 (1999).
99. Alves da Costa C, Mattson MP, Ancolio K. and Checler F. The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis a function independent of the presenilinase-derived N-terminal counterpart. J Biol Chem 278: 12064-12069 (2003).
100. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, Chumakov I, Cohen D, Lannfelt L, Fraser PE, Rommens JM. and H. St Georges-Hyslop P. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376: 775-778 (1995).
101. Marcon G, Giaccone G, Cupidi C, Balestrieri M, Beltrami CA, Finato N, Bergonzi P, Sorbi S, Bugiani O. and Tagliavini F. Neuropathological and clinical phenotype of an italian Alzheimer family with M239V mutation of presenilin 2 gene. J Neuropathol & Exp Neurol 63: 199-209 (2004).
102. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu C, Jondro PD, Schmidt SD, Wang K, Crowley AC, Fu YH, Guenette D. Galas SY, Nemens E, Wisjman EM, Bird TD, Schellenberg GD. and Tanzi R. Candidate gene for the chromosome 1 familial Alzheimer's disease locus Science 269: 973-977 (1995).
103. Lao JI, Beyer K, Fernandez-Novoa L. and Cacabelos R. A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a spanish patient with late onset Alzheimer's disease. Neurogenetics 1: 293-296 (1998).
104. Cruts M, van Duijn CM, Backhovens H, Van den broek M, Wehner M, Serneels L, Sherrington R, Hutton M, Hardy J, St George-Hyslop P, Hofman A. and Van Broeckhoven C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of Alzheimer disease. Hum Mol Gen 7: 43-51 (1998).
105. Finckh U, Muller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, Binetti G, Alberici A, Hock C, Nitsch RM. and Gal A. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Hum Mol Gen 66: 110-117 (2000).
106. Tedde A, Nacmias B, Ciantelli M, Forleo P, Cellini E, Bagnoli S, Piccini C, Caffarra P, Ghidoni E, Paganini M, Bracco L. and Sorbi S. Identification of new presenilin gene mutations in early-onset familial Alzheimer disease. Arch Neurol 60: 1541-1544 (2003).
107. Ezquerra M, Lleo A, Castellvi M, Queralt R, Santacruz P, Pastor P, Molinuevo J, Blesa R. and Oliva R. A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. Arch Neurol 60: 1149-1151 (2003).
108. Zekanovski C, Styczynska M, Peplonska B, Gabryelewicz T, Religa D, Ilkowski J, Kijanowska-Haladyna B, Kotapka-Minc S, Mikkelsen S, Pfeffer A, Barczak A, Luczywek E, Wasiak B, Chodakowska-Zebrowska M, Gustaw K, Laczkowski J, Sobow T, Kuznicki J. and Barcikowska M. Mutations in presenilin 1 presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol 184: 991-996 (2003).